Product Details for NDA 205879
INVOKAMET XR (CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE)
50MG;500MG
Marketing Status: Prescription
50MG;1GM
Marketing Status: Prescription
150MG;500MG
Marketing Status: Prescription
150MG;1GM
Marketing Status: Prescription
50MG;500MG
Marketing Status: Prescription
Active Ingredient: CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE
Proprietary Name: INVOKAMET XR
Dosage Form; Route of Administration: TABLET, EXTENDED RELEASE; ORAL
Strength: 50MG;500MG
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N205879
Product Number: 001
Approval Date: Sep 20, 2016
Applicant Holder Full Name: JANSSEN PHARMACEUTICALS INC
Marketing Status: Prescription
Patent and Exclusivity Information
INVOKAMET XR (CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE)
Proprietary Name: INVOKAMET XR
Dosage Form; Route of Administration: TABLET, EXTENDED RELEASE; ORAL
Strength: 50MG;500MG
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N205879
Product Number: 001
Approval Date: Sep 20, 2016
Applicant Holder Full Name: JANSSEN PHARMACEUTICALS INC
Marketing Status: Prescription
Patent and Exclusivity Information
50MG;1GM
Marketing Status: Prescription
Active Ingredient: CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE
Proprietary Name: INVOKAMET XR
Dosage Form; Route of Administration: TABLET, EXTENDED RELEASE; ORAL
Strength: 50MG;1GM
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N205879
Product Number: 002
Approval Date: Sep 20, 2016
Applicant Holder Full Name: JANSSEN PHARMACEUTICALS INC
Marketing Status: Prescription
Patent and Exclusivity Information
INVOKAMET XR (CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE)
Proprietary Name: INVOKAMET XR
Dosage Form; Route of Administration: TABLET, EXTENDED RELEASE; ORAL
Strength: 50MG;1GM
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N205879
Product Number: 002
Approval Date: Sep 20, 2016
Applicant Holder Full Name: JANSSEN PHARMACEUTICALS INC
Marketing Status: Prescription
Patent and Exclusivity Information
150MG;500MG
Marketing Status: Prescription
Active Ingredient: CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE
Proprietary Name: INVOKAMET XR
Dosage Form; Route of Administration: TABLET, EXTENDED RELEASE; ORAL
Strength: 150MG;500MG
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N205879
Product Number: 003
Approval Date: Sep 20, 2016
Applicant Holder Full Name: JANSSEN PHARMACEUTICALS INC
Marketing Status: Prescription
Patent and Exclusivity Information
INVOKAMET XR (CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE)
Proprietary Name: INVOKAMET XR
Dosage Form; Route of Administration: TABLET, EXTENDED RELEASE; ORAL
Strength: 150MG;500MG
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N205879
Product Number: 003
Approval Date: Sep 20, 2016
Applicant Holder Full Name: JANSSEN PHARMACEUTICALS INC
Marketing Status: Prescription
Patent and Exclusivity Information
150MG;1GM
Marketing Status: Prescription
Active Ingredient: CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE
Proprietary Name: INVOKAMET XR
Dosage Form; Route of Administration: TABLET, EXTENDED RELEASE; ORAL
Strength: 150MG;1GM
Reference Listed Drug: Yes
Reference Standard: Yes
TE Code:
Application Number: N205879
Product Number: 004
Approval Date: Sep 20, 2016
Applicant Holder Full Name: JANSSEN PHARMACEUTICALS INC
Marketing Status: Prescription
Patent and Exclusivity Information
Proprietary Name: INVOKAMET XR
Dosage Form; Route of Administration: TABLET, EXTENDED RELEASE; ORAL
Strength: 150MG;1GM
Reference Listed Drug: Yes
Reference Standard: Yes
TE Code:
Application Number: N205879
Product Number: 004
Approval Date: Sep 20, 2016
Applicant Holder Full Name: JANSSEN PHARMACEUTICALS INC
Marketing Status: Prescription
Patent and Exclusivity Information